An Ultrathin Biodegradable Polymer Stent Is Superior for Patients with STEMI

Target lesion failure rates at 1 year were lower with this device than with standard drug-eluting stent in patients with ST-segment elevation myocardial infarction.

Biodegradable polymers for everolimus drug elution combined with ultrathin-strut stents (BPEES) might mitigate inflammation and promote more rapid endothelialization than current third-generation, durable-polymer, sirolimus-eluting stents (DPSES). In a randomized, investigator-initiated, Swiss study sponsored by the BPEES manufacturer (NCT02579031), investigators compared BPEES to DPSES in 1300 patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (mean age, 63; diabetes, 12%; 25% women).

At 1 year of follow-up, the primary endpoint of target lesion failure (composite of cardiac death, target vessel myocardial reinfarction, and target lesion revascularization) occurred in signi…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)